


# A cell-based neuroprotection assay targeting poly (ADP-ribose) polymerase (PARP) reveals oncology-based potency ranking of clinically used PARP inhibitors (PARPi)

Saheed O. Benson<sup>1</sup>, Fyaz M.D. Ismail<sup>1</sup>, Amos A. Fatokun<sup>1</sup>

<sup>1</sup>Centre for Natural Products Discovery (CNPD), School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

## 1. Introduction

- Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) selectively kill cancer cells that harbour mutation in tumour suppressor genes, such as *BRCA1* and *BRCA2*.
- Four PARPi are currently used in the clinic as monotherapy for *BRCA*-mutated cancers.
- PARPi have also been suggested for repurposing for neurological and neurodegenerative indications, wherein excessive PARP activation leads to neuronal death and PARP inhibition is neuroprotective [1].




## 2. Aim

To examine whether our cell-based assay, originally designed for interrogating PARP-mediated neuronal death, is adaptable to other application contexts by revealing the established, oncology-related rank order of potencies for the PARPi.

## 3. Methods

- PARP-dependent cell death was induced in HeLa cells by treatment with the alkylating agent, *N*-methyl-*N*-nitro-*N*-nitrosoguanidine (MNNG) (50µM, 25 minutes) [2].
- Cells were treated with each of four PARP inhibitors: Olaparib, niraparib, rucaparib and talazoparib (each up to 10µM).
- Protection against cell death (evidence of PARP inhibition) was assessed 24 h after MNNG treatment using the MTT assay.
- EC<sub>50</sub> values reported as means ± SEM; n=3-6.
- Statistical analysis (in GraphPad 9.2.0): ANOVA with Tukey's post-hoc test; P<0.05 considered statistically significant.

## 4. Results



**Figure 1:** Each of the four PARPi (5-100nM) shows concentration-dependent protection against MNNG-induced reduction in cell viability, as quantified by the MTT assay. \*\*\*P<0.001 with respect to the control; ###P<0.001, ##P<0.05 and #P<0.01 with respect to MNNG alone.

**Table 1:** EC<sub>50</sub> values (Mean ± SEM) for the four PARPi and their relative potencies. The EC<sub>50</sub> values revealed their potencies in the following order: **talazoparib** > **rucaparib** > **niraparib** > **olaparib**.

	EC <sub>50</sub> /IC <sub>50</sub> (nM)		Potency ratio vs. olaparib	
	EC <sub>50</sub> (our <b>cell-based</b> assay)	IC <sub>50</sub> (literature-reported, <b>cell-free</b> assay)	Our <b>Cell-based</b> Assay	Literature- reported <b>Cell-free</b> Assay
<b>Olaparib</b>	23.1 ± 8.9	5	1	1
<b>Niraparib</b>	17.1 ± 2.0	3.8	1.3	1.3
<b>Rucaparib</b>	8.4 ± 1.8	2	2.8	2.5
<b>Talazoparib</b>	3.6 ± 0.3	0.57	6.4	8.8

## 5. Conclusions

- Although the cell-based EC<sub>50</sub> values are higher than the literature-reported IC<sub>50</sub> values in cell-free assays, the order of potency was the same and the relative potencies compared to olaparib were similar [2].
- Our cell-based assay is therefore robust for the characterisation of PARPi for oncological and repurposing applications.

## References:

1. Fatokun AA et al. (2013). Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. *Br. J. Pharmacol.* **169**: 1263-78.
2. Slade D (2020). PARP and PARG inhibitors in cancer treatment. *Genes Dev.* **34**:360-394.